Skip to content
OpenCapital
Get started

Ultragenyx Pharmaceutical RARE Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Amgen logo
AmgenAMGN
$559M+10.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$173.38M-34.4%
Arrowhead Research logo
Arrowhead ResearchARWR
$188.52M+1.5%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
$423.31M+80.0%
Moderna logo
ModernaMRNA
$1.91B+17.4%

Other financials

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Total debt$36.0M-10.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation

See full
Market cap$2.83B-39.4%
P/S4.2×-3.7×

Profitability

See full
Gross margin97.2%—
Operating margin-83.8%-3.0pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×—
Current ratio2×-0.4×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Ultragenyx Pharmaceutical’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ultragenyx Pharmaceutical's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ultragenyx Pharmaceutical's cash & equivalents?
Ultragenyx Pharmaceutical (RARE) reported cash & equivalents of $175M in Q1 2026.
How has Ultragenyx Pharmaceutical's cash & equivalents changed year-over-year?
Ultragenyx Pharmaceutical's cash & equivalents increased by 37.8% year-over-year, from $127M to $175M.
What is the long-term trend for Ultragenyx Pharmaceutical's cash & equivalents?
Over 5 years (2020 to 2025), Ultragenyx Pharmaceutical's cash & equivalents has grown at a -10.0% compound annual growth rate (CAGR), from $713.53M to $421M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.